In one multi-institutional, open-label, phase I dose-escalation study in patients with EGFR-mutated (exon 19 deletion and L858R mutation) NSCLC and a BIM deletion polymorphism, Vorinostat was associated with gefitinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.